CA2400205A1 - Modification de biopolymeres pour administration amelioree de medicaments - Google Patents

Modification de biopolymeres pour administration amelioree de medicaments Download PDF

Info

Publication number
CA2400205A1
CA2400205A1 CA002400205A CA2400205A CA2400205A1 CA 2400205 A1 CA2400205 A1 CA 2400205A1 CA 002400205 A CA002400205 A CA 002400205A CA 2400205 A CA2400205 A CA 2400205A CA 2400205 A1 CA2400205 A1 CA 2400205A1
Authority
CA
Canada
Prior art keywords
biopolymer
group
conjugate
therapeutic agent
chemically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400205A
Other languages
English (en)
Inventor
Pericles Calias
Robert J. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400205A1 publication Critical patent/CA2400205A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne un conjugué biologiquement actif, qui contient un biopolymère et un agent thérapeutique réunis par une liaison disulfure. Le conjugué, formulé en une composition pharmaceutique avec un excipient approprié, possède une stabilité et une activité in vivo accrues et peut être ciblé sur diverses cellules, divers tissus et organes.
CA002400205A 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments Abandoned CA2400205A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18255800P 2000-02-15 2000-02-15
US60/182,558 2000-02-15
US21150800P 2000-06-14 2000-06-14
US60/211,508 2000-06-14
PCT/US2001/004925 WO2001060412A2 (fr) 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments

Publications (1)

Publication Number Publication Date
CA2400205A1 true CA2400205A1 (fr) 2001-08-23

Family

ID=26878197

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400205A Abandoned CA2400205A1 (fr) 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments

Country Status (6)

Country Link
EP (1) EP1263472A2 (fr)
JP (1) JP2003522806A (fr)
AU (1) AU2001238346A1 (fr)
CA (1) CA2400205A1 (fr)
IL (1) IL151024A0 (fr)
WO (1) WO2001060412A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525621A (ja) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2004060404A1 (fr) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Vecteur de medicament
EP1633778B1 (fr) * 2003-06-05 2013-09-11 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Conjugues d'acide poly-gamma-glutamique pour solliciter des reponses immunitaires dirigees contre des bacilles
JP4695591B2 (ja) * 2003-06-18 2011-06-08 アポセンス リミテッド アポトーシス細胞を選択的に標的化する方法、および、それらに用いられる低分子物質リガンド
US20070092550A1 (en) * 2003-10-10 2007-04-26 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
US7625736B2 (en) 2004-06-04 2009-12-01 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing immunogenic conjugates
US8143391B2 (en) 2004-09-07 2012-03-27 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
EP1877099B1 (fr) 2005-04-06 2012-09-19 Genzyme Corporation Conjugués thérapeutiques comprenant une enzyme lysosomale, l'acide polysialique et un agent de ciblage
US20080206276A1 (en) 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
WO2008089403A2 (fr) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprenant un groupe aminooxy et des conjugués de celui-ci
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
HUE033169T2 (en) 2011-03-03 2017-11-28 Chugai Pharmaceutical Co Ltd Amino carboxylic acid modified hyaluronic acid derivative
WO2012140650A2 (fr) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugués de carboxy polysaccharides avec des facteurs de croissance des fibroblastes et variants de ceux-ci
WO2014038641A1 (fr) 2012-09-05 2014-03-13 中外製薬株式会社 Dérivé d'acide hyaluronique ayant un groupe stéryle d'acides aminés introduit dans celui-ci
KR102049568B1 (ko) * 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7759291A (en) * 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
EP0611306B1 (fr) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobines utilisees comme agents administrateurs de medicaments
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
NZ262679A (en) * 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5354853A (en) 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
CN1263473A (zh) * 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production

Also Published As

Publication number Publication date
WO2001060412A3 (fr) 2002-01-24
JP2003522806A (ja) 2003-07-29
EP1263472A2 (fr) 2002-12-11
AU2001238346A1 (en) 2001-08-27
IL151024A0 (en) 2003-02-12
WO2001060412A2 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
US6749865B2 (en) Modification of biopolymers for improved drug delivery
AU2021201321B2 (en) Preparation and/or formulation of proteins cross-linked with polysaccharides
CA2400205A1 (fr) Modification de biopolymeres pour administration amelioree de medicaments
US5527893A (en) Water insoluble derivatives of polyanionic polysaccharides
US5874417A (en) Functionalized derivatives of hyaluronic acid
US7029688B2 (en) Methods and compositions to prevent formation of adhesions in biological tissues
US4937270A (en) Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) Water insoluble derivatives of polyanionic polysaccharides
US6884788B2 (en) Thiol-modified hyaluronan
US6030958A (en) Water insoluble derivatives of hyaluronic acid
US6235726B1 (en) Water insoluble derivatives of polyanionic polysaccharides
EP0640622A1 (fr) Derive de polysaccharide et vehicule de medicament
WO1992000105A1 (fr) Derives d'acide hyaluronique insolubles dans l'eau
US20080292664A1 (en) Hydrogels and Hyaluronic Acid and Alpha, Beta-Polyaspartyl-Hydrazide and Their Biomedical and Pharmaceutical Uses
US20110262492A1 (en) Catalyst and byproduct-free native chemical ligation using cyclic thioester precursors
CA2140108A1 (fr) Conjugues de collagene et de polymeres synthetiques ayant une distribution regularisee de diametres des fibres

Legal Events

Date Code Title Description
FZDE Discontinued